Actively Recruiting
Dinner Time for Obesity and Prediabetes
Led by Johns Hopkins University · Updated on 2026-04-13
32
Participants Needed
2
Research Sites
247 weeks
Total Duration
On this page
Sponsors
J
Johns Hopkins University
Lead Sponsor
N
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborating Sponsor
AI-Summary
What this Trial Is About
Obesity and its metabolic complications are leading causes of global morbidity and mortality. Evidence is mounting that inappropriate timing of food intake contributes to obesity. Specifically, late eating is associated with greater weight gain and metabolic syndrome. However, the mechanism by which late eating harms metabolism is not fully understood but may be related to mis-timing of food intake in relation to the body's endogenous circadian rhythm. Conversely, harmonization of eating timing with endogenous circadian rhythm may optimize metabolic health. In this study the investigators will use gold-standard methods of characterizing circadian rhythm in humans to examine the metabolic impacts food timing relative to endogenous circadian rhythm.
CONDITIONS
Official Title
Dinner Time for Obesity and Prediabetes
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Healthy male and female adults aged 18-50 with BMI between 18 and 24.9 kg/m2 (Normal-Weight Healthy group)
- Male and female adults aged 18-50 with BMI 30 kg/m2 or higher and prediabetes (Obesity-Prediabetes group)
- Ability to understand and comply with study procedures for the entire study duration
- Fully mobile participants
You will not qualify if you...
- Sleep disorders including insomnia, untreated moderate-severe sleep apnea, restless leg syndrome, or narcolepsy
- Night shift work
- Routine bedtime later than 1:00 AM or mid-sleep on free days later than 5:00 AM or DLMO later than midnight
- Gastroesophageal reflux disease affecting dinner tolerance close to bedtime
- Active smoking
- Current drug or alcohol use/dependence interfering with study adherence
- Diabetes (type 1 or 2) or use of diabetes medications other than metformin
- Metabolic or cardiovascular diseases, cancer, thyroid disease
- Hemoglobin A1c above 5.7% for Normal-Weight Healthy group or above 6.5% for Obesity-Prediabetes group
- Hemoglobin below 10 g/dL
- Self-reported kidney disease
- Known inherited metabolic disorders
- Pregnancy or lactation
- Peri-menopausal or post-menopausal females as defined by hormone levels or menstrual history
- Professional or collegiate athletes
- Recent travel across time zones without adequate recovery
- Weight under 40 kg or over 180 kg
- Gastrointestinal disorders or history of gastrointestinal surgery
- Swallowing disorders
- Use of medications affecting metabolism or circadian rhythm
- Presence of cardiac pacemaker or electro-medical implants
- Exposure to strong electromagnetic fields during ingestible thermosensor use
- Weight change of 5% or more in last 3 months
- Current participation in weight loss programs
- Prior bariatric surgery
- Strict dietary restrictions such as vegetarian or kosher diet
- History of significant intravenous access issues
- Non-English speaking individuals
- Other conditions as determined by the principal investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Johns Hopkins Bayview Medical Center
Baltimore, Maryland, United States, 21224
Actively Recruiting
2
National Institutes of Health Clinical Center
Bethesda, Maryland, United States, 20892
Not Yet Recruiting
Research Team
A
Athena Mavronis
CONTACT
M
Mariah Potocki
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
BASIC_SCIENCE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here